Although several studies showed promising results utilizing MEK inhibitors in benign PN, single-agent MEK inhibition has not been nearly as effective in MPNST models [32,85], likely due to adaptive signaling leading to drug resistance [86]. The gene discussed is MAP2K7; the disease is poikiloderma with neutropenia.